Related Experiment Videos
A new monoclonal antibody recognizing anthracyclinic molecule
A Balsari1, D Morelli, S Menard
1Department of Biomedical Sciences and Biotechnologies, University of Brescia, Italy.
Anticancer Research
|January 1, 1990
Summary
Researchers developed monoclonal antibodies (MAbs) to overcome Doxorubicin's immunosuppressive effects. One MAb, MAD11, specifically targets the aromatic ring D of anthracyclines, offering a new tool for drug research.
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Background:
- Doxorubicin (DXR) exhibits immunosuppressive properties, limiting its therapeutic applications.
- Monoclonal antibodies (MAbs) offer potential for targeted therapeutic strategies.
- Anthracycline derivatives share structural similarities, presenting challenges for selective targeting.
Purpose of the Study:
- To develop and characterize monoclonal antibodies (MAbs) that circumvent the immunosuppressive effects of Doxorubicin (DXR).
- To obtain MAbs that selectively recognize DXR and related anthracycline derivatives.
- To differentiate MAbs based on their epitope binding specificities within the anthracycline structure.
Main Methods:
- Somatic hybridization techniques were employed to generate hybridoma cell lines producing MAbs.
- Immunological assays were performed to confirm antibody reactivity with DXR and anthracycline derivatives.
- Epitope mapping studies were conducted to determine the specific binding sites of the generated MAbs.
Main Results:
- Monoclonal antibodies (MAbs) capable of reacting with Doxorubicin (DXR) were successfully obtained, circumventing its immunosuppressive effects.
- A specific MAb, designated MAD11, was characterized as an IgG2 antibody.
- MAD11 selectively recognizes epitopes on the aromatic ring D of the anthracycline molecule, distinguishing it from other MAbs like MAD2 which targets ring A.
Conclusions:
- The development of MAbs like MAD11 provides a novel approach to target Doxorubicin (DXR) and its derivatives.
- MAD11's selective binding to the aromatic ring D offers a distinct characteristic for antibody-based applications in anthracycline research.
- These findings pave the way for developing more specific diagnostic or therapeutic tools related to anthracycline compounds.